Karyopharm therapeutics says qtrly loss per share $0.67

Karyopharm therapeutics - qtrly loss per share $0.67.karyopharm therapeutics - qtrly product sales from xpovio $12.8 million.q3 earnings per share view $-0.83 -- refinitiv ibes data.karyopharm therapeutics - pivotal phase 3 boston study on track for top-line data by early 2020.karyopharm therapeutics - on track to file by 2019 end, an nda in the u.s. for selinexor requesting accelerated approval.karyopharm therapeutics - cash, cash equivalents, restricted cash and investments as of sept. 30, of $270.3 million.karyopharm therapeutics - expects fy non-gaap operating expenses $200 million to $210 million.karyopharm therapeutics - expects cash, cash equivalents, investments, revenue from xpovio sales to be sufficient to fund operations into middle of 2021.
KPTI Ratings Summary
KPTI Quant Ranking